Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 729

1.

Autoantibodies Specific for Galactose-Deficient IgA1 in IgA Vasculitis With Nephritis.

Suzuki H, Moldoveanu Z, Julian BA, Wyatt RJ, Novak J.

Kidney Int Rep. 2019 Aug 30;4(12):1717-1724. doi: 10.1016/j.ekir.2019.08.015. eCollection 2019 Dec.

2.

The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy.

Rizk DV, Maillard N, Julian BA, Knoppova B, Green TJ, Novak J, Wyatt RJ.

Front Immunol. 2019 Mar 19;10:504. doi: 10.3389/fimmu.2019.00504. eCollection 2019. Review.

3.

Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy.

Hastings MC, Bursac Z, Julian BA, Villa Baca E, Featherston J, Woodford SY, Bailey L, Wyatt RJ.

Kidney Int Rep. 2017 Aug 24;3(1):99-104. doi: 10.1016/j.ekir.2017.08.008. eCollection 2018 Jan.

4.

Serial Galactose-Deficient IgA1 Levels in Children with IgA Nephropathy and Healthy Controls.

Sanders JT, Hastings MC, Moldoveanu Z, Novak J, Julian BA, Bursac Z, Wyatt RJ.

Int J Nephrol. 2017;2017:8210641. doi: 10.1155/2017/8210641. Epub 2017 Nov 26.

5.

Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA Nephropathy.

Yamada K, Huang ZQ, Raska M, Reily C, Anderson JC, Suzuki H, Ueda H, Moldoveanu Z, Kiryluk K, Suzuki Y, Wyatt RJ, Tomino Y, Gharavi AG, Weinmann A, Julian BA, Willey CD, Novak J.

Kidney Int Rep. 2017 Jul 19;2(6):1194-1207. doi: 10.1016/j.ekir.2017.07.002. eCollection 2017 Nov.

6.

Are we ready for targeted therapy for IgA nephropathy?

Wyatt RJ.

Lancet. 2017 May 27;389(10084):2083-2084. doi: 10.1016/S0140-6736(17)30820-6. Epub 2017 Mar 28. No abstract available.

PMID:
28363482
7.

GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway.

Kiryluk K, Li Y, Moldoveanu Z, Suzuki H, Reily C, Hou P, Xie J, Mladkova N, Prakash S, Fischman C, Shapiro S, LeDesma RA, Bradbury D, Ionita-Laza I, Eitner F, Rauen T, Maillard N, Berthoux F, Floege J, Chen N, Zhang H, Scolari F, Wyatt RJ, Julian BA, Gharavi AG, Novak J.

PLoS Genet. 2017 Feb 10;13(2):e1006609. doi: 10.1371/journal.pgen.1006609. eCollection 2017 Feb.

8.

Somatic Mutations Modulate Autoantibodies against Galactose-Deficient IgA1 in IgA Nephropathy.

Huang ZQ, Raska M, Stewart TJ, Reily C, King RG, Crossman DK, Crowley MR, Hargett A, Zhang Z, Suzuki H, Hall S, Wyatt RJ, Julian BA, Renfrow MB, Gharavi AG, Novak J.

J Am Soc Nephrol. 2016 Nov;27(11):3278-3284. Epub 2016 Mar 10.

9.

Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?

Suzuki H, Allegri L, Suzuki Y, Hall S, Moldoveanu Z, Wyatt RJ, Novak J, Julian BA.

Dis Markers. 2016;2016:7806438. doi: 10.1155/2016/7806438. Epub 2016 Aug 28.

10.

Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.

Hogg RJ, Bay RC, Jennette JC, Sibley R, Kumar S, Fervenza FC, Appel G, Cattran D, Fischer D, Hurley RM, Cerda J, Carter B, Jung B, Hernandez G, Gipson D, Wyatt RJ.

Am J Kidney Dis. 2015 Nov;66(5):783-91. doi: 10.1053/j.ajkd.2015.06.013. Epub 2015 Jul 21.

PMID:
26209543
11.

Current Understanding of the Role of Complement in IgA Nephropathy.

Maillard N, Wyatt RJ, Julian BA, Kiryluk K, Gharavi A, Fremeaux-Bacchi V, Novak J.

J Am Soc Nephrol. 2015 Jul;26(7):1503-12. doi: 10.1681/ASN.2014101000. Epub 2015 Feb 18. Review.

12.

Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens.

Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, Fasel D, Lata S, Prakash S, Shapiro S, Fischman C, Snyder HJ, Appel G, Izzi C, Viola BF, Dallera N, Del Vecchio L, Barlassina C, Salvi E, Bertinetto FE, Amoroso A, Savoldi S, Rocchietti M, Amore A, Peruzzi L, Coppo R, Salvadori M, Ravani P, Magistroni R, Ghiggeri GM, Caridi G, Bodria M, Lugani F, Allegri L, Delsante M, Maiorana M, Magnano A, Frasca G, Boer E, Boscutti G, Ponticelli C, Mignani R, Marcantoni C, Di Landro D, Santoro D, Pani A, Polci R, Feriozzi S, Chicca S, Galliani M, Gigante M, Gesualdo L, Zamboli P, Battaglia GG, Garozzo M, Maixnerová D, Tesar V, Eitner F, Rauen T, Floege J, Kovacs T, Nagy J, Mucha K, Pączek L, Zaniew M, Mizerska-Wasiak M, Roszkowska-Blaim M, Pawlaczyk K, Gale D, Barratt J, Thibaudin L, Berthoux F, Canaud G, Boland A, Metzger M, Panzer U, Suzuki H, Goto S, Narita I, Caliskan Y, Xie J, Hou P, Chen N, Zhang H, Wyatt RJ, Novak J, Julian BA, Feehally J, Stengel B, Cusi D, Lifton RP, Gharavi AG.

Nat Genet. 2014 Nov;46(11):1187-96. doi: 10.1038/ng.3118. Epub 2014 Oct 12.

13.

Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes.

Suzuki H, Raska M, Yamada K, Moldoveanu Z, Julian BA, Wyatt RJ, Tomino Y, Gharavi AG, Novak J.

J Biol Chem. 2014 Feb 21;289(8):5330-9. doi: 10.1074/jbc.M113.512277. Epub 2014 Jan 7.

14.

Biomarkers in IgA nephropathy: relationship to pathogenetic hits.

Hastings MC, Moldoveanu Z, Suzuki H, Berthoux F, Julian BA, Sanders JT, Renfrow MB, Novak J, Wyatt RJ.

Expert Opin Med Diagn. 2013 Nov;7(6):615-27. doi: 10.1517/17530059.2013.856878. Review.

15.

IgA nephropathy.

Wyatt RJ, Julian BA.

N Engl J Med. 2013 Jun 20;368(25):2402-14. doi: 10.1056/NEJMra1206793. Review. No abstract available.

PMID:
23782179
16.

Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathy.

Eison TM, Hastings MC, Moldoveanu Z, Sanders JT, Gaber L, Walker PD, Lau KK, Julian BA, Novak J, Wyatt RJ.

Clin Nephrol. 2012 Dec;78(6):465-9. doi: 10.5414/CN107423.

17.

Has the incidence of childhood steroid sensitive nephrotic syndrome changed?

Spencer JD, Hastings MC, Wyatt RJ, Ault BH.

Clin Nephrol. 2012 Aug;78(2):112-5.

PMID:
22790455
18.

Serum galactose-deficient IgA1 level is not associated with proteinuria in children with IgA nephropathy.

Hastings MC, Afshan S, Sanders JT, Kane O, Eison TM, Lau KK, Moldoveanu Z, Julian BA, Novak J, Wyatt RJ.

Int J Nephrol. 2012;2012:315467. doi: 10.1155/2012/315467. Epub 2012 Jun 17.

19.

Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis.

Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, Snyder HJ, Choi M, Hou P, Scolari F, Izzi C, Gigante M, Gesualdo L, Savoldi S, Amoroso A, Cusi D, Zamboli P, Julian BA, Novak J, Wyatt RJ, Mucha K, Perola M, Kristiansson K, Viktorin A, Magnusson PK, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Boland A, Metzger M, Thibaudin L, Wanner C, Jager KJ, Goto S, Maixnerova D, Karnib HH, Nagy J, Panzer U, Xie J, Chen N, Tesar V, Narita I, Berthoux F, Floege J, Stengel B, Zhang H, Lifton RP, Gharavi AG.

PLoS Genet. 2012;8(6):e1002765. doi: 10.1371/journal.pgen.1002765. Epub 2012 Jun 21.

20.

Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5.

Scholl UI, Nelson-Williams C, Yue P, Grekin R, Wyatt RJ, Dillon MJ, Couch R, Hammer LK, Harley FL, Farhi A, Wang WH, Lifton RP.

Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2533-8. doi: 10.1073/pnas.1121407109. Epub 2012 Jan 30.

21.

APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy.

Papeta N, Kiryluk K, Patel A, Sterken R, Kacak N, Snyder HJ, Imus PH, Mhatre AN, Lawani AK, Julian BA, Wyatt RJ, Novak J, Wyatt CM, Ross MJ, Winston JA, Klotman ME, Cohen DJ, Appel GB, D'Agati VD, Klotman PE, Gharavi AG.

J Am Soc Nephrol. 2011 Nov;22(11):1991-6. doi: 10.1681/ASN.2011040434. Epub 2011 Oct 13.

22.

The pathophysiology of IgA nephropathy.

Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA.

J Am Soc Nephrol. 2011 Oct;22(10):1795-803. doi: 10.1681/ASN.2011050464. Epub 2011 Sep 23. Review.

23.

Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucosal immune system.

Novak J, Moldoveanu Z, Julian BA, Raska M, Wyatt RJ, Suzuki Y, Tomino Y, Gharavi AG, Mestecky J, Suzuki H.

Adv Otorhinolaryngol. 2011;72:60-3. doi: 10.1159/000324607. Epub 2011 Aug 18. Review.

PMID:
21865691
24.

IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cells.

Novak J, Raskova Kafkova L, Suzuki H, Tomana M, Matousovic K, Brown R, Hall S, Sanders JT, Eison TM, Moldoveanu Z, Novak L, Novak Z, Mayne R, Julian BA, Mestecky J, Wyatt RJ.

Nephrol Dial Transplant. 2011 Nov;26(11):3451-7. doi: 10.1093/ndt/gfr448. Epub 2011 Aug 9.

25.

Genome-wide association study identifies susceptibility loci for IgA nephropathy.

Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, Sanna-Cherchi S, Men CJ, Julian BA, Wyatt RJ, Novak J, He JC, Wang H, Lv J, Zhu L, Wang W, Wang Z, Yasuno K, Gunel M, Mane S, Umlauf S, Tikhonova I, Beerman I, Savoldi S, Magistroni R, Ghiggeri GM, Bodria M, Lugani F, Ravani P, Ponticelli C, Allegri L, Boscutti G, Frasca G, Amore A, Peruzzi L, Coppo R, Izzi C, Viola BF, Prati E, Salvadori M, Mignani R, Gesualdo L, Bertinetto F, Mesiano P, Amoroso A, Scolari F, Chen N, Zhang H, Lifton RP.

Nat Genet. 2011 Mar 13;43(4):321-7. doi: 10.1038/ng.787.

26.

Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis.

Kiryluk K, Moldoveanu Z, Sanders JT, Eison TM, Suzuki H, Julian BA, Novak J, Gharavi AG, Wyatt RJ.

Kidney Int. 2011 Jul;80(1):79-87. doi: 10.1038/ki.2011.16. Epub 2011 Feb 16.

27.

Post-streptococcal acute glomerulonephritis in children: clinical features and pathogenesis.

Eison TM, Ault BH, Jones DP, Chesney RW, Wyatt RJ.

Pediatr Nephrol. 2011 Feb;26(2):165-80. doi: 10.1007/s00467-010-1554-6. Epub 2010 Jul 23. Review.

PMID:
20652330
28.

Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability.

Hastings MC, Moldoveanu Z, Julian BA, Novak J, Sanders JT, McGlothan KR, Gharavi AG, Wyatt RJ.

Clin J Am Soc Nephrol. 2010 Nov;5(11):2069-74. doi: 10.2215/CJN.03270410. Epub 2010 Jul 15.

29.

Genetic studies of IgA nephropathy: past, present, and future.

Kiryluk K, Julian BA, Wyatt RJ, Scolari F, Zhang H, Novak J, Gharavi AG.

Pediatr Nephrol. 2010 Nov;25(11):2257-68. doi: 10.1007/s00467-010-1500-7. Epub 2010 Apr 13. Review.

30.

Familial IgA nephropathy in southeastern Kentucky.

Lavigne KA, Woodford SY, Barker CV, Julian BA, Novak J, Moldoveanu Z, Gharavi AG, Wyatt RJ.

Clin Nephrol. 2010 Feb;73(2):115-21.

31.

Pathogenesis of Henoch-Schönlein purpura nephritis.

Lau KK, Suzuki H, Novak J, Wyatt RJ.

Pediatr Nephrol. 2010 Jan;25(1):19-26. doi: 10.1007/s00467-009-1230-x. Epub 2009 Jun 13. Review. Erratum in: Pediatr Nephrol. 2010 Jan;25(1):179.

32.

Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.

Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J.

J Clin Invest. 2009 Jun;119(6):1668-77. doi: 10.1172/JCI38468. Epub 2009 May 26.

33.

Control of aquaporin 2 expression in collecting ducts of quail kidneys.

Lau KK, Yang Y, Cook GA, Wyatt RJ, Nishimura H.

Gen Comp Endocrinol. 2009 Feb 1;160(3):288-94. doi: 10.1016/j.ygcen.2008.12.007. Epub 2008 Dec 24.

PMID:
19135443
34.

IgA nephropathy and Henoch-Schönlein purpura nephritis.

Sanders JT, Wyatt RJ.

Curr Opin Pediatr. 2008 Apr;20(2):163-70. doi: 10.1097/MOP.0b013e3282f4308b. Review.

PMID:
18332712
35.

Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy.

Gharavi AG, Moldoveanu Z, Wyatt RJ, Barker CV, Woodford SY, Lifton RP, Mestecky J, Novak J, Julian BA.

J Am Soc Nephrol. 2008 May;19(5):1008-14. doi: 10.1681/ASN.2007091052. Epub 2008 Feb 13.

36.

Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy.

Mestecky J, Tomana M, Moldoveanu Z, Julian BA, Suzuki H, Matousovic K, Renfrow MB, Novak L, Wyatt RJ, Novak J.

Kidney Blood Press Res. 2008;31(1):29-37. doi: 10.1159/000112922. Epub 2008 Jan 8. Review.

37.

IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1.

Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, Julian BA, Tomana M, Wyatt RJ, Edberg JC, Alarcón GS, Kimberly RP, Tomino Y, Mestecky J, Novak J.

J Clin Invest. 2008 Feb;118(2):629-39. doi: 10.1172/JCI33189.

38.

Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases.

Julian BA, Wittke S, Novak J, Good DM, Coon JJ, Kellmann M, Zürbig P, Schiffer E, Haubitz M, Moldoveanu Z, Calcatera SM, Wyatt RJ, Sýkora J, Sládková E, Hes O, Mischak H, McGuire BM.

Electrophoresis. 2007 Dec;28(23):4469-83.

PMID:
18004714
39.

Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura.

Lau KK, Wyatt RJ, Moldoveanu Z, Tomana M, Julian BA, Hogg RJ, Lee JY, Huang WQ, Mestecky J, Novak J.

Pediatr Nephrol. 2007 Dec;22(12):2067-72. Epub 2007 Oct 18.

PMID:
17943324
40.

Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseases.

Julian BA, Wittke S, Haubitz M, Zürbig P, Schiffer E, McGuire BM, Wyatt RJ, Novak J.

World J Urol. 2007 Oct;25(5):467-76. Epub 2007 Jul 10. Review.

PMID:
17619884
41.

The genetics of IgA nephropathy.

Beerman I, Novak J, Wyatt RJ, Julian BA, Gharavi AG.

Nat Clin Pract Nephrol. 2007 Jun;3(6):325-38. Review.

PMID:
17525715
42.

IgA nephropathy and Henoch-Schoenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells.

Novak J, Moldoveanu Z, Renfrow MB, Yanagihara T, Suzuki H, Raska M, Hall S, Brown R, Huang WQ, Goepfert A, Kilian M, Poulsen K, Tomana M, Wyatt RJ, Julian BA, Mestecky J.

Contrib Nephrol. 2007;157:134-8. Review.

PMID:
17495451
43.

IgA nephropathy: characterization of IgG antibodies specific for galactose-deficient IgA1.

Suzuki H, Moldoveanu Z, Hall S, Brown R, Julian BA, Wyatt RJ, Tomana M, Tomino Y, Novak J, Mestecky J.

Contrib Nephrol. 2007;157:129-33. Review.

PMID:
17495450
44.

IgA nephropathy: a clinical overview.

Julian BA, Wyatt RJ, Matousovic K, Moldoveanu Z, Mestecky J, Novak J.

Contrib Nephrol. 2007;157:19-26. Review.

PMID:
17495433
45.

Identification and characterization of CMP-NeuAc:GalNAc-IgA1 alpha2,6-sialyltransferase in IgA1-producing cells.

Raska M, Moldoveanu Z, Suzuki H, Brown R, Kulhavy R, Andrasi J, Hall S, Vu HL, Carlsson F, Lindahl G, Tomana M, Julian BA, Wyatt RJ, Mestecky J, Novak J.

J Mol Biol. 2007 May 25;369(1):69-78. Epub 2007 Mar 12.

46.

Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels.

Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, Huang WQ, Anreddy SR, Hall S, Hastings MC, Lau KK, Cook WJ, Novak J.

Kidney Int. 2007 Jun;71(11):1148-54. Epub 2007 Mar 7.

47.

Diagnosis of de novo localized thrombotic microangiopathy by surveillance biopsy.

Hastings MC, Wyatt RJ, Ault BH, Jones DP, Lau KK, Gaber AO, Gaber LW.

Pediatr Nephrol. 2007 May;22(5):742-6. Epub 2007 Jan 10.

PMID:
17216252
48.

Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy.

Schachter AD, Benfield MR, Wyatt RJ, Grimm PC, Fennell RS, Herrin JT, Lirenman DS, McDonald RA, Munoz-Arizpe R, Harmon WE.

Pediatr Transplant. 2006 Dec;10(8):914-9.

49.

Five years' experience with thymoglobulin induction in a pediatric renal transplant population.

Colleen Hastings M, Wyatt RJ, Lau KK, Jones DP, Powell SL, Hays DW, Gaber LW, Osama Gaber A, Ault BH.

Pediatr Transplant. 2006 Nov;10(7):805-10.

PMID:
17032426
50.

Renal survival in pediatric patients with IgA nephropathy.

Hastings MC, Delos Santos NM, Wyatt RJ.

Pediatr Nephrol. 2007 Feb;22(2):317-8. Epub 2006 Sep 21. No abstract available.

PMID:
17024389

Supplemental Content

Loading ...
Support Center